GlobeNewswire

Record gold sales in the first quarter of 2018 high grade intercepts in the Guiro mine.

Dela

QUÉBEC CITY, April 11, 2018 (GLOBE NEWSWIRE) -- Komet Resources Inc. is delighted to have generated record gold sales of CA$1,354,000 in the first quarter of 2018, with a production cash cost of CA$1,038,000 for 27.5 kilos of gold from the Guiro mine located in Burkina Faso. This occurs after only two quarters of operation since the active start of the optimized process. The modernization of the Guiro plant was completed at the end of the second quarter 2017, with, among other things, the installation of an Acacia intensive leaching reactor, the establishment of an in-series triple gravity concentrator system, the refurbishment of a larger capacity ball mill with a larger capacity and the installation of a hydrocyclone to operate in closed circuit mode.

Recent Development at the Guiro Mine

The company has recently obtained the results of eight diamond drill holes conducted as part of the ongoing resource development of the Guiro mine in Burkina Faso (see table below). These include the following intersections: 0.68 m grading 180.50 g/t Au in borehole Gu2017dd05, 1.24 m grading 10.36 g/t Au in borehole Gu2017dd03 and 1.68 m grading 17.11 g/t Au in borehole Gu2017dd06. Gu2017dd04 borehole also intercepted mineralization below the 4-east level in the mine, 12.5 meters west to the previously known Gu2015dd16 hole of 4.3 m grading 9.2 g/t. The results of this survey confirm the continuity of the vein as defined in the published NI43-101 resource calculation. Mining planning will be in this way better defined. The experience in the Guiro mine allows us to give an influence of 12.5 meters on both sides of a hole. Future development in this area then allows us to plan more than 7,100 t at 7.79 g/t Auundiluted. The vein is still open at least toward the west and at depth.

Furthermore, the Gu2017dd06 borehole located between two previously mined stopes on level 2, confirms a hitherto unknown continuity due to inaccessibility. This will allow us to mine more than 1000 t at 17.11 g/t Au undiluted. This excellent result will be followed by verification of the upper vertical continuity of level 2 in this new mineralized horizon.

These results follow those on the west development of the mine, announced in the January 29, 2018, press release.

Ongoing development

Komet's team is pursuing development westward at level 3 to reach the western gold ore shoot and aims in particular to join, within 30 m, the strike of the previously announced Gu2015dd35 drill intersection (1.4 m at 31 g/t Au). The development to the east at level 4 is also underway to complete the 25 meters required to reach the mineralization mentioned above. At the junction of level 3, a total of 35 m out of the planned 70m north development is underway and will allow reaching a mineralized zone parallel to the Guiro vein, mentioned in historical works, and allow positioning of the new pneumatic drill (Bazooka) for exploration at depth of the Guiro vein.

Finally, at the main shaft intersection at level 4, the development of a gallery is in progress in order to reach the parallel vein named "Guiro Sud" which gave results by core drilling such as 57 cm at 10.62 g/t Au and 52 cm at 8.64 g/t Au. See the May 25, 2017, press release for more information.

Mr André Gagné, president and CEO stated: "The development of the Guiro mine, as well as the nearby discoveries, confirm the excellent gold potential within our reach. In addition, the good gold sales results of the first quarter confirm the company's vision: 'Discovering by producing!'"

Summary table of drilling results:

Hole number From (m) To (m) Interval (m) True width (m) Au (g/t)
Gu2017dd01 161.00 162.65 2.65 1.43 1.22
incl 161.00 161.75 0.75 0.65 2.09
incl 162.45 162.65 0.20 0.17 1.96
Gu2017dd03 167.20 168.44 1.24 1.07 10.36
incl 167.70 168.44 0.74 0.64 16.73
Gu2017dd04 154.38 159.00 4.62 4.00 1.47
incl 155.00 155.38 0.38 0.33 7.32
Gu2017dd05 58.82 60.65 1.83 1.58 67.58
incl 59.32 60.00 0.68 0.59 180.50
Gu2017dd06 73.95 75.63 1.68 1.45 17.11
incl 73.95 74.50 0.55 0.48 13.12
incl 74.50 74.88 0.38 0.33 7.05
incl 74.88 75.63 0.75 0.65 25.13

The samples assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company's mine site laboratory and by plating on 50 g aliquots with atomic absorption (ppm for gold) at BIGGS Global in Burkina Faso. Sampling and supervision of the works were carried out on the site by qualified technicians. Quality assurance and quality control program and interpretation of results are done by qualified geologists according to a 43-101 compliant QA / QC program and industry best practices, including the introduction of samples reference, sterile samples and duplicates for each batch of 20 samples analyzed.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: 
André Gagné, President and CEO / +1-581-300-1666 / a.gagne@kometgold.com / Skype: andregagne11

Relations Publiques Paradox Inc. / Carl Desjardins / +1-514-341-0408 / carldesjardins@paradox-pr.ca

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the geological information presented herein.

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet's control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet's management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/0f952ff1-87ac-454d-a02f-9df5fbedf5db




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Komet Resources Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum